Overview

A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Status:
Not yet recruiting

Trial end date:
2022-09-05

Target enrollment:

Participant gender:

Summary

BI 1810631 trial formulation 1 (TF1) is currently used in clinical trials, and intended commercial formulation (iCF) is planned to be used in the future in clinical trials and on the market. This trial intends to bridge pharmacokinetics (PK) between the two formulations. Moreover the trial intends to inform on the effect of food and of the proton pump inhibitor rabeprazole on the PK of BI 1810631 in order to inform management of food and concomitant medications.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Rabeprazole